Aromatase inhibitor develops high risk to cardiovascular disease for postmenopausal breast cancer patients
Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.
Read more on News-Medical-Net
Orignal From: Aromatase inhibitor develops high risk to cardiovascular disease for postmenopausal breast cancer patients
Post a Comment